Cargando…

Managing Hypertension in the elderly: What’s new?

Hypertension is the leading modifiable risk factor for cardiovascular events and mortality in the world. Hypertension is a major risk factor for cardiovascular events and mortality in the elderly. The 2017 American College of Cardiology/American Heart Association hypertension guidelines recommend tr...

Descripción completa

Detalles Bibliográficos
Autor principal: Aronow, Wilbert S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8315374/
https://www.ncbi.nlm.nih.gov/pubmed/34327445
http://dx.doi.org/10.1016/j.ajpc.2020.100001
_version_ 1783729708649676800
author Aronow, Wilbert S.
author_facet Aronow, Wilbert S.
author_sort Aronow, Wilbert S.
collection PubMed
description Hypertension is the leading modifiable risk factor for cardiovascular events and mortality in the world. Hypertension is a major risk factor for cardiovascular events and mortality in the elderly. The 2017 American College of Cardiology/American Heart Association hypertension guidelines recommend treatment of noninstitutionalized ambulatory community-dwelling persons aged 65 years and older with an average systolic blood pressure of 130 ​mm Hg or higher or a diastolic blood pressure of 80 ​mm Hg or higher with lifestyle measures plus antihypertensive drug to lower the blood pressure to less than 130/80 ​mm Hg For elderly adults with hypertension and a high burden of comorbidities and limited life expectancy, clinical judgment, patient preference, and a team-based approach to assess risk/benefit is reasonable for decisions about the intensity of SBP lowering and the choice of antihypertensive drugs to use for treatment. Randomized clinical trials need to be performed in frail elderly patients with hypertension living in nursing homes. Elderly frail persons with prevalent and frequent falls, marked cognitive impairment, and multiple comorbidities requiring multiple antihypertensive drugs also need to be included in randomized clinical trials. Data on patients older than 85 years treated for hypertension are also sparse. These patients need clinical trial data. Finally, the effect of different antihypertensive drugs on clinical outcomes including serious adverse events needs to be investigated in elderly frail patients with hypertension and different comorbidities.
format Online
Article
Text
id pubmed-8315374
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-83153742021-07-28 Managing Hypertension in the elderly: What’s new? Aronow, Wilbert S. Am J Prev Cardiol State-of-the-Art Review Hypertension is the leading modifiable risk factor for cardiovascular events and mortality in the world. Hypertension is a major risk factor for cardiovascular events and mortality in the elderly. The 2017 American College of Cardiology/American Heart Association hypertension guidelines recommend treatment of noninstitutionalized ambulatory community-dwelling persons aged 65 years and older with an average systolic blood pressure of 130 ​mm Hg or higher or a diastolic blood pressure of 80 ​mm Hg or higher with lifestyle measures plus antihypertensive drug to lower the blood pressure to less than 130/80 ​mm Hg For elderly adults with hypertension and a high burden of comorbidities and limited life expectancy, clinical judgment, patient preference, and a team-based approach to assess risk/benefit is reasonable for decisions about the intensity of SBP lowering and the choice of antihypertensive drugs to use for treatment. Randomized clinical trials need to be performed in frail elderly patients with hypertension living in nursing homes. Elderly frail persons with prevalent and frequent falls, marked cognitive impairment, and multiple comorbidities requiring multiple antihypertensive drugs also need to be included in randomized clinical trials. Data on patients older than 85 years treated for hypertension are also sparse. These patients need clinical trial data. Finally, the effect of different antihypertensive drugs on clinical outcomes including serious adverse events needs to be investigated in elderly frail patients with hypertension and different comorbidities. Elsevier 2020-05-01 /pmc/articles/PMC8315374/ /pubmed/34327445 http://dx.doi.org/10.1016/j.ajpc.2020.100001 Text en © 2020 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle State-of-the-Art Review
Aronow, Wilbert S.
Managing Hypertension in the elderly: What’s new?
title Managing Hypertension in the elderly: What’s new?
title_full Managing Hypertension in the elderly: What’s new?
title_fullStr Managing Hypertension in the elderly: What’s new?
title_full_unstemmed Managing Hypertension in the elderly: What’s new?
title_short Managing Hypertension in the elderly: What’s new?
title_sort managing hypertension in the elderly: what’s new?
topic State-of-the-Art Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8315374/
https://www.ncbi.nlm.nih.gov/pubmed/34327445
http://dx.doi.org/10.1016/j.ajpc.2020.100001
work_keys_str_mv AT aronowwilberts managinghypertensionintheelderlywhatsnew